Multiple promoters and inhibitors mediate angiogenesis, the formation of new blood vessels, and these factors represent potential targets for impeding vessel growth in tumors. Vascular endothelial growth factor (VEGF) is a potent angiogenic factor targeted in anti-angiogenic cancer therapies. In addition, thrombospondin-1 (TSP1) is a major endogenous inhibitor of angiogenesis, and TSP1 mimetics are being developed as an alternative type of anti-angiogenic agent. The combination of bevacizumab, an anti-VEGF agent, and ABT-510, a TSP1 mimetic, has been tested in clinical trials to treat advanced solid tumors. However, the patients' responses are highly variable and show disappointing outcomes. To obtain mechanistic insight into the effects of this combination anti-angiogenic therapy, we have constructed a novel wholebody pharmacokinetic model including the VEGF and TSP1 reaction networks. Using this molecular-detailed model, we investigated how the combination anti-angiogenic therapy changes the extracellular angiogenic balance in cancer patients and how the effect of the combination therapy is influenced by tumor receptor expression. Overall, this model complements the clinical administration of combination anti-angiogenic therapy, highlights the role of tumor receptor variability in the heterogeneous responses to anti-angiogenic therapy and identifies the tumor receptor profiles that correlate with a high likelihood of a positive response to combination therapy. In addition, this study provides novel understanding of the VEGF-TSP1 balance in cancer patients at the systems-level and could be further used to optimize combination anti-angiogenic therapy.
Quick Guide to Equations and Assumptions
The mechanistic model represents human cancer patients using three compartments: normal tissue ("normal," represented by skeletal muscle), the vasculature ("blood"), and diseased tissue ("tumor") ( Fig. 1A) . The soluble species are assumed to diffuse within the available interstitial space very fast compared to the timescale of the biochemical reactions 1 , thus the compartment is well-mixed with uniform distribution of molecules within the compartment volume. The characterization of the species dynamics is based on the principles of mass action kinetics and biological transport. Given the complexity of the system, a rule-based modeling approach is used to construct the model 2 . The biological reaction rules are defined in BioNetGen, which automatically generates the model of ordinary differential equations (ODEs). The defined rules generate 561 species and 2618 reactions. We implemented and solved the ODEs in MATLAB (model file provided in Supplementary File S1). Here, we list several generic forms of equations as an overview of ODE model.
i. Key equations
! = ! ! + !"#,!"#$ [ ] ! − !"# ! − !"#,! ! − !"# + !"
ii. Major assumptions
Our model is a significant extension of previous models. Several new soluble species are introduced into the model for the TSP1 reaction network. We assume that the newly introduced species have the same transport rates as the VEGF. In the model, the luminal endothelium is distinct from abluminal endothelium, and we assume the receptors are equally distributed on the two sides of endothelial cells. The pharmacokinetic data of bevacizumab and ABT-510 during combination therapy is not available. Therefore, we assume their pharmacokinetics are not influenced by one other during the combination therapy and are the same as what has been measured in clinical trials using them as single agents. To match the pharmacokinetic data of ABT-510, we assume the drug has a bioavailability of 30%.
Introduction:
Angiogenesis is a hallmark of cancer that facilitates tumor progression in many aspects 5 . Tumor growth relies on the formation of new blood vessels to enable waste exchange and to deliver oxygen and nutrients to the tumor. In addition, angiogenesis increases the likelihood of metastasis by enabling tumor cells to enter the bloodstream and disperse to other sites in the body 6 . Considering the outstanding importance of angiogenesis for tumor development, antiangiogenic therapy was designed to starve the tumor of its nutrient supply and limit its growth 7 .
Tumor angiogenesis is controlled by both pro-angiogenic and anti-angiogenic signaling [8] [9] [10] .
Common anti-angiogenic therapy uses single agents to reduce the pro-angiogenic signals. The primary anti-angiogenic agents being used in the clinic inhibit signaling mediated by the vascular endothelial growth factor-A (VEGF), a potent promoter of angiogenesis. However, this approach is not effective in all cancers. For example, bevacizumab, a monoclonal antibody that binds VEGF, is no longer approved for breast cancer treatment, and sunitinib, a tyrosine kinase inhibitor that targets VEGF receptors and other growth factor receptors, has also shown limited success 11 . These limitations of anti-VEGF treatment prompt the need for alternative approaches to target the tumor vasculature. One alternate anti-angiogenic approach is to enhance the signal of anti-angiogenic factors. Thrombospondin-1 (TSP1) is one of the most studied endogenous inhibitors of angiogenesis and has been shown to inhibit vascular growth and tumorigenesis in preclinical trials [12] [13] [14] . Inspired by the effect of TSP1, TSP1 mimetics were developed for tumor treatment 15 . One such drug, named as ABT-510, reached Phase II clinical trials. However, ABT-510 failed to show clear evidence of efficacy and is no longer tested as a single-agent drug in clinical development 16, 17 .
The disappointing outcomes of clinical studies of anti-angiogenic drugs as single agents prompt the study of combination anti-angiogenic therapy. Administering a combination of antiangiogenic agents that simultaneously target multiple angiogenic signals is expected to achieve efficient and durable suppression of angiogenesis by strong shifting the relative balance of inducers and inhibitors of angiogenesis to oppose the "angiogenic switch" 18, 19 . The combination of agents targeting different pathways might also prevent tumors from leveraging complementary pathways to escape anti-angiogenic treatment. With this in mind, the TSP1 mimetic was clinically tested in combination with bevacizumab in patients with advanced solid tumors. However, patients displayed a heterogeneous response to this combination therapy 20 :
one patient had a partial response and only 32% of the patients had prolonged stable disease (≥ 6 months). Unfortunately, the mechanisms driving these disappointing results were not elucidated in the trial . Three fundamental questions remain: do the levels of TSP1 and VEGF   balance one another in tumor tissue, how does combination therapy influence this VEGF-TSP1 balance, and does inter-patient heterogeneity lead to significantly different responses.
Answering these questions contributes to our understanding of the action of combination therapy. In addition, considering the angiogenic balance at the levels of tissue, organs and the whole body can help us optimize anti-angiogenic therapy. In this study, we address these questions using a computational systems biology model.
Mathematical models provide a useful framework to study the response to anti-angiogenic treatment, complementing experimental and clinical studies. In particular, the effects of anti-VEGF agents on VEGF and its receptors have been intensively investigated using computational modeling 21 . A model of the VEGF-receptor system was previously used to illustrate the counterintuitive increasing of VEGF after anti-VEGF treatment 22 , and our recent model of TSP1 and VEGF interactions in tumor tissue predicts the effects of various strategies mimicking TSP1's anti-angiogenic properties 23 .
Here, we significantly expand on previous work to generate a novel whole-body model of the VEGF-TSP1 interaction network. We apply the model to understand how the angiogenic balance of VEGF and TSP1 is modulated by bevacizumab and ABT-510 combination therapy.
We also use the model to investigate the impact of tumor receptor heterogeneity, which has been observed experimentally [24] [25] [26] [27] , on the response to combination anti-angiogenic therapy.
The model predicts the receptors that can serve as predictive tissue biomarkers to distinguish the patients in which the combination anti-angiogenic therapy will elicit a strong therapeutic response. Overall, we establish a robust computational framework to predict the effects of antiangiogenic therapies and understand clinical observations.
Materials and Methods

Rule Based Model of VEGF-TSP1 Reaction Network
The derivation of the ODE model is described in the Quick Guide to Equations and Assumptions.
Here, we briefly summarize the defined rules that govern the molecular interactions and corresponding reactions ( Fig. 1B-G) . Following our previous works, the model includes two active VEGF isoforms (VEGF 165 and VEGF 121 ). The inactive form, VEGF 114 , is the product of proteolytic cleavage of VEGF 165 . Two predominant VEGF receptors, VEGFR1 and VEGFR2 (R1 and R2), and neuropilin co-receptors, NRP1 and NRP2 (N1 and N2), are considered ( Fig. 1B) .
TSP1 binds to its receptors, CD36, CD47, low density lipoprotein receptor-related protein 1 (LRP1) and α x β 1 intergrins (β1, a generic form representing several species) ( Fig. 1C) . We also include matrix metalloproteinase, MMP, species (MMP3, MMP9 and proMMP9), which promote VEGF cleavage. TSP1 impedes the activation of MMP9 ( Fig. 1D) . Glycosaminoglycan (GAG) chains reside in the interstitial space, representing the extracellular matrix, as well as in the cellular basement membranes. GAG chains are able to bind and sequester TSP1 and VEGF 165 ( Fig. 1E) . The α-2-macroglobulin (α2M) species, a protease inhibitor, is confined to the blood compartment, where it binds to VEGF (Fig. 1F) . The soluble species are introduced to the system by being secreted by cells and are removed from the system through degradation and clearance from the blood. Receptors are uniformly distributed on the cell surfaces and can be internalized by the cell and recycled back to the surface. The total number for each type of receptor is assumed to be conserved at every simulated time point. Transport of soluble species between the compartments is mediated by transcapillary permeability and lymphatic flow. ). The densities of these receptors were randomly chosen from a uniform distribution within a range of 10-fold above and below the baseline value. We generated 1,000 different combinations of receptor density profiles, representing 1,000 unique cancer patients. We ran the model for each of the receptor profiles with anti-angiogenic treatment to examine how the response to treatment varies across the 1,000 parameter sets.
Model Parameters
Combination Therapy of Bevacizumab and ABT-510
The combination therapy of bevacizumab and ABT-510 is simulated by mimicking the administration strategy used in clinical trials 20 . We first allowed the model to reach steady state (this occurs within 24 hours) before the start of treatment. We then simulated one cycle of the combination therapy: bevacizumab was administered once at the beginning of the cycle; ABT-510 was administered every 12 hours for 14 days. Bevacizumab was given at a dose of 10 mg/kg through intravenous infusion lasting 90 minutes, while ABT-510 was administered at 100 mg twice daily through subcutaneous injection. The kinetic parameters of bevacizumab are the same as those used in our previous work 28 , which can capture the clinically-measured pharmacokinetic data 34 (Supplementary Fig. S1A ). The bolus of ABT-510 was given directly to a subcutaneous compartment 35 (assumed to be a reservoir with a volume of 30 cm 3 ), and it is subsequently transported into blood. To fit the pharmacokinetic data of TSP1 36 ( Supplementary   Fig. S1B ), we assumed the bioavailability of ABT-510 is 30% in subcutaneous injection 37 . The transportation between the subcutaneous and blood compartments is unidirectional and is assumed to occur at the same as the rate transport between the normal and blood compartments. The degradation rate of ABT-510 follows its measured circulation half-time in the human body (1.2 hours). ABT-510 binds to TSP1 receptor CD36 to induce an anti-angiogenic signal 38 (Fig. 1G) . Since ABT-510 is a TSP1-derived peptidomimetic, we assume it has the same affinity to CD36 as TSP1.
Quantification of Combination Effect
Commonly used dose-effect-based approaches to quantify drug combination effects rely on the mathematical framework known as Loewe Additivity 39 . It calculates the combination of dose a for drug X and dose b for drug Y that can produce the same effect as dose A of drug X alone and dose B of drug Y alone. The combination effect of drug X and drug Y can be expressed as:
where CI is the combination index. We evaluate the combination effect (Fc) of 10 mg/kg of bevacizumab and 100 mg of ABT-510. Thus, a = 10 mg/Kg and b = 100 mg. We change the doses of bevacizumab and ABT-510 to get the dose-effect curve of single-agent treatments and find the Dose A and Dose B corresponding to Fc. A CI less than one indicates synergy between the two drugs, a CI equal to one represents simple additivity, and CI greater than one indicates antagonism.
Partial Least Squares Regression
Partial least squares regression (PLSR) relates input variables to output variables by maximizing the correlation between the variables. This is accomplished by projecting the output variables onto new dimensions (principal components, PCs), which are linear combinations of the inputs. We use PLSR to investigate the relationship between tumor receptor numbers and the response to anti-angiogenic therapy (the fold-change in the angiogenic ratio in the tumor tissue, termed F). The PLSR model is trained and validated with the 1,000 different combinations of tumor receptor densities (inputs) and the corresponding responses to treatment generated by the three-compartment systems biology model (outputs). The receptor values are normalized by dividing by the lower bound of the sampling range. Since the receptor numbers are sampled from a uniform distribution within 10-fold above and below the baseline value, the normalized receptor values range from 1 to 100. The nonlinear iterative partial least squares (NIPALS) algorithm was used to implement the PLSR analysis 40 . Leave-one-out cross validation is applied to quantify the predictive capability of the PLSR model. Furthermore, we calculated the "variable importance of projection" (VIP) for each input variable 41 , which is the weighted sum of each input's contribution to the output. As such, the VIP evaluates the overall importance of an input variable in predicting the output. VIP values greater than one indicate variables that are important for predicting the output response.
Results:
Angiogenic balance is predicted to shift during combination therapy
We apply the compartmental model to predict how the angiogenic signal changes with antiangiogenic treatment. We simulate one cycle (14 days) of combination therapy, following the protocol used in clinical trial 20 . Bevacizumab was given at a dose of 10 mg/kg through intravenous infusion lasting 90 minutes. ABT-510 was administered at 100 mg every 12 hours for 14 days. The concentrations of unbound ("free") VEGF and TSP1 over time, along with dynamics of the "angiogenic ratio", are reported to show the change of angiogenic signals during combination therapy (Fig. 2) . The angiogenic ratio is the number of pro-angiogenic complexes over the number of anti-angiogenic complexes (see Methods). If the angiogenic ratio is greater than one, the compartment is considered to be in a pro-angiogenic state.
After one cycle of the combination therapy, the concentration of free VEGF is predicted to decrease in all three compartments ( Fig. 2A) . The tumor VEGF level changes from 149 pM to 14 pM after one treatment cycle. The levels of free VEGF in plasma and normal tissue decreased from 1.6 pM to 1.2 pM and from 1.0 pM to 0.9 pM, respectively. In contrast, the free active TSP1 level in all three compartments is highly stable throughout the whole treatment cycle ( Fig. 2B) , remaining at 117 pM, 96 pM, and 66 pM in the tumor, blood, and normal compartments, respectively. This indicates that the combination therapy does not affect the free TSP1 level in human body. The experimental measurements from clinical study also show that the level of TSP1 does not significantly change 20 , which validates this prediction. However, the combination therapy is predicted to significantly reduce the angiogenic ratio in all compartments.
Before treatment, the angiogenic ratio ( Fig. 2C) is predicted to highly favor angiogenesis in tumor and blood, where the ratios are 14.4 and 6.2, respectively. In comparison, the angiogenic ratio is almost balanced in the rest of the body (1.3 in normal compartment). The values of the angiogenic ratios at the end of the treatment cycle are 6.6, 2.0, and 0.6 in the tumor, blood, and normal compartments. Thus, following treatment, the angiogenic balance is significantly reduced but still favors angiogenesis in tumor tissue and blood and opposes angiogenesis in normal tissue. In all compartments, the angiogenic ratio is predicted to oscillate during the treatment. Since the ABT-510 drug has a short half-life (1.2 hours in circulation), it requires a high frequency of administration (twice-daily injections), which causes the angiogenic ratio to oscillate following each injection. Specifically, the angiogenic ratio decreases to a low level for a short time after the administration of ABT-510 and goes back to a medium level before the next dose of ABT-510.
To get detailed insight into how the angiogenic ratio varies, we report the change of all the tumor angiogenic complexes in combination therapy and single agent treatment ( Supplementary Fig. S2 ). VEGF can bind to four different receptors, including VEGF receptor 1 (R1), VEGF receptor 2 (R2), neuropilin-1 (N1) and neuropilin-2 (N2). Thus, four different types of pro-angiogenic complexes are formed. TSP1 binds to four different receptors, including CD47, CD36, LRP1 and β1) to produce four types of anti-angiogenic complexes. Our predictions show that bevacizumab promotes a decrease in the pro-angiogenic complex involving VEGFR1 ( Fig.   S2A ) and ABT-510 drives an increase in the anti-angiogenic complex involving CD36 (Fig.   S2B) . The absolute levels of other angiogenic complexes only show small changes. The effect of the two agents in combination on the formation of angiogenic complexes is a superimposition of their individual effects ( Fig. S2C ).
Therapeutic response varies due to tumor receptor heterogeneity
To examine the impact of tumor receptor heterogeneity, we varied the number of VEGF and TSP1 receptors in the tumor tissue (both on tumor cells and diseased endothelial cells). We set the density of each receptor by sampling within two orders of magnitude of the baseline value.
This variability in the receptor number influences the dynamics of free VEGF, free TSP1, and the angiogenic ratio, as shown in Supplementary Fig. S3 . We use the "fold-change" of free VEGF, free TSP1, and the angiogenic ratio to characterize the response to combination treatment. The fold-change is the post-treatment level compared to the pre-treatment level.
When the fold-change is less than one, the quantity has decreased after treatment. We further define a therapeutic response to be when the fold-change of free VEGF or the angiogenic ratio is less than one. The model predicts that combination treatment elicits a therapeutic effect for all of the receptor levels simulated. That is, the fold-change of free VEGF and the angiogenic ratio are predicted to be lower than one in all three compartments (Fig. 3A) , indicating that free VEGF and the angiogenic ratio decrease after treatment.
Model predictions show that the response level of the fold-change in tumor varies depending on the tumor receptor profile. Different combinations of sampled parameter values represent patients with different tumor receptor profiles. The model predicts a wide range of fold-changes for the angiogenic ratio and free VEGF in the tumor compartment ( Fig. 3A) , which indicates that different tumor receptor profiles lead to different responses to the combination therapy.
Furthermore, the skewed distribution of the fold-changes of the tumor angiogenic ratio (F) (Fig.   3B, orange) shows that the majority (83%) of the sampled tumor profiles lead to intermediate responses with fold-change ranging from 0.5 to 1. A smaller percentage of profiles (17%) have a strong response to treatment (F < 0.5). Interestingly, there are some outliers for which combination treatment significantly decreases the pro-angiogenic signal, with fold-changes of free VEGF or angiogenic ratio much lower than one. These results imply that particular tumor receptor profiles could have a strong therapeutic response to combination therapy. In singleagent anti-angiogenic tumor therapy (ABT-510 or bevacizumab treatment alone), heterogeneous responses are also observed (Fig. 3B, green and purple) . Thus, the response to single-agent treatment also varies depending on the tumor receptor profile.
Tumor receptor heterogeneity influences treatment outcomes in other aspects. Firstly, variability in the tumor receptor numbers could affect the targeting of combination anti-angiogenic therapy.
Our simulations show combination therapy is not always efficiently targeting tumor angiogenesis.
For most cases, the fold-change of the angiogenic ratio in healthy tissue and in blood is lower than in the tumor (Fig. 3A) . This indicates treatment is more effective in shifting the angiogenic balance in healthy tissue rather than in the tumor. For these tumor patients, the combination therapy is targeting physiological angiogenesis instead of tumor angiogenesis. Interestingly, this insight is not captured by solely examining the fold-change of VEGF. Secondly, tumor receptor heterogeneity influences the effect of combination therapy on individual angiogenic pathways.
The model predicts that the fold-change of the VEGFR2-and neuropilin-1-containing proangiogenic complexes in tumor could be higher than one for some sampled cases ( Supplementary Fig. S4 ). This indicates that for some tumor receptor profiles, the proangiogenic signaling pathway of VEGFR2 or NRP-1 will be enhanced after treatment instead of inhibited. Similar results are seen when simulating bevacizumab treatment (data not shown).
Interestingly, these unintended outcomes following bevacizumab treatment predicted by the model have been observed clinically: a substantial increase in phosphorylated VEGFR2 42 and variable changes in phosphorylated VEGFR2 in the clinical trial of the combination antiangiogenic therapy 20 .
Tumor receptor heterogeneity affects the combination effect
We used the model to compare the response to single-and dual-agent therapy and find that the response to combination therapy is related to the response to single-agent treatment (Fig. 4A) .
The color changes from red to yellow along the diagonal direction (from upper right to lower left)
shows that the response to combination treatment (Fc) improves when the response to either single-agent treatment is higher. This indicates that a better response to single-agent treatment may correspond to a better response to combination therapy. We then examined the superiority of the drug combination compared to the single agents. The color of the points in Fig. 4B indicates the difference between the response to combination therapy and the best response amongst the two single-agent treatments. Although this difference changes depending on the tumor receptor profile, for all sampled cases, the difference is higher than zero. This indicates that the response to combination therapy is better than single agent treatment. Thus, if only considering the fold-change of tumor angiogenic ratio (F), the combination therapy of bevacizumab and ABT-510 is superior to single-agent therapy for all of the sampled tumor receptor profiles.
We explicitly calculated the combination effect to determine if the action of the two drugs is synergistic or additive. We selected four sets of tumor receptor profiles (Fig. 4A, triangles) and calculated the combination index (CI) of the Loewe additivity (see Methods). These are representative cases corresponding to patients that respond well to ABT-510 alone ("1"), bevacizumab alone ("2"), or combination therapy ("3"), and one patient that does not respond well to either drug ("4"). The calculated CI values are different for these four tumor profiles ( Fig.   4C) , where the combination effect could be synergistic (i.e., patient 3 with CI = 0.65) or nearly additive (i.e., patients 1 and 2 have CI = 0.89; patient 4 has CI = 0.97). Thus, the combination effect of bevacizumab and ABT-510 is also affected by tumor receptor heterogeneity.
Therapeutic response depends on tumor cell VEGFR1, CD36 and CD47 expression
Given the observed impact of tumor receptor heterogeneity in the predictions from the mechanistic model, we explored if we can use tissue biomarkers (tumor receptor levels) to determine the response to combination anti-angiogenic therapy a priori. We used partial least squares regression (PLSR) to characterize the association between tumor receptor levels and the response to combination therapy (the fold-change in the angiogenic ratio in the tumor).
Specifically, we established a predictive PLSR model that estimates the response to combination therapy using the tumor angiogenic receptor profile (Supplementary Fig. S5A ).
We The variable importance of projection (VIP) score was calculated to find which variables, across the entire PLSR model, most significantly contribute to determining the response to combination therapy 41 . VEGFR1, CD36 and CD47 levels on tumor cells were found to be important for explaining the response, as they have VIP scores higher than one (Fig. 5A) . The two nonlinear terms of tumor cell receptor numbers are also identified as important variables. We found that all of the receptors on tumor endothelial cells have VIP score lower than 0.5, indicating that tumor endothelial cell receptor expression was not as influential as receptor expression on tumor cells in predicting the response to combination therapy. Plotting the values of the receptors with VIP scores greater than one versus the response to combination therapy shows that lower VEGFR1 expression, lower CD47 expression and higher CD36 expression on tumor cells correlate with higher response (Fig. 5B-D) . This indicates the patients with low tumor cell VEGFR1 or CD47 expression or high tumor cell CD36 expression are likely to show a stronger response to combination therapy than others. The associations between response and other receptors are not pronounced (Supplementary Fig. S6) . The therapeutic response is also related to the two nonlinear terms in a monotonic fashion ( Fig. 5E-F) . Interestingly, although the response to treatment exhibits a trend that correlates with certain individual receptors, the data highly deviates from the LOWESS smoothing of the data (Fig. 5, black lines) . This indicates that none of the 16 receptor variables can accurately predict the response alone, and the variability in the expression of a single receptor cannot account for all of the variability in the response to combination anti-angiogenic therapy.
Discussion:
The investigation of anti-angiogenic therapy greatly benefits from computational models that provide quantitative insight into the heterogeneous responses to therapy. In the present study, This work uses a molecular-based pharmacokinetic model to bridge the heterogeneous response of anti-angiogenic therapy with tumor receptor heterogeneity. Tumor angiogenic receptor heterogeneity has been observed in various settings. Qualitative information on the differential expression of angiogenic receptors from different tumor samples is reported in Human Protein Atlas Database 26, 27 . Quantitative measurements also show the cell-to-cell variations in the density of VEGF receptors across different cell lines 24, 25 . This heterogeneity is thought to influence prognosis and response to treatment, which has been validated experimentally. The VEGFR2 heterogeneity was proved to influence the response to an antiangiogenic cyclophosphamide treatment in a pre-clinical model 43 . The inter-patient VEGFR1
and neuropilin heterogeneity has been associated with the response to bevacizumab treatment in search for biomarkers 44, 45 . To complement the preclinical and clinical studies, this work provides a possible quantitative characterization of the mechanisms leading to the clinically observed heterogeneous responses to combination anti-angiogenic therapy 7, 11, 46 . The model predicts that after one cycle of treatment, the fold-change of the angiogenic ratio in tumor tissue varies widely depending on the tumor receptor levels, which indicates tumor receptor heterogeneity could contribute to heterogeneous response and should be considered when developing more effective and personalized anti-angiogenic therapy.
The work helps identify biomarkers that predict response to anti-angiogenic treatment. The heterogeneous response to anti-angiogenic therapy is a major drawback not limited to the combination therapy of bevacizumab and ABT-510, but generally to all anti-angiogenic agents 7, 46 . However, despite substantial research 47 , there is currently no reliable biomarker for identifying patients for which anti-angiogenic therapy will be effective. The PLSR analysis in our study showed that the levels of CD36, CD47, and VEGFR1 on tumor cells are potential biomarkers to select the patients who will likely respond to combination treatment. These receptors are shown to have a pronounced impact on the response: low expression of VEGFR1 and CD47 and high expression of CD36 all associate with high response to combination treatment. Interestingly, the relationship between VEGFR1 and the effect of bevacizumab has also been observed in clinical trial. Fountzilas et al. report that intra-tumoral VEGFR1 overexpression was an indicator for poor survival in metastatic breast cancer patients receiving bevacizumab and chemotherapy 48 , supporting the finding in our study. In addition to identifying these biomarkers, our study emphasizes the importance of the integration of information from multiple receptors to accurately predict the response. We showed that the expression of a single receptor is not able to fully account for the heterogeneous response to therapy. Instead, a comprehensive analysis that incorporates multiple biomarkers is more appropriate. In the experimental and clinical practice of biomarker discovery, it is commonly accepted that a single biomarker is not able to predict anti-angiogenic treatment efficacy 47 . Our findings support this stance and demonstrate that a computational approach could help identify biomarkers by providing systematic understanding of the response to treatment.
Given the molecular detail of the model, we gain mechanistic insight into the model predictions.
For example, we can understand how the individual tumor receptor populations change in response to anti-angiogenic therapy, insight that explains why VEGFR1, CD36, and CD47 are potential biomarkers. VEGFR1 has been supported as a possible in situ predictive biomarker for anti-VEGF agents in both preclinical and clinical settings [47] [48] [49] . Our model predicts that the pro-angiogenic complexes involving VEGFR1 have the most more important role in the response to bevacizumab treatment. The pro-angiogenic complexes involving VEGFR1 significantly decrease after the administration of bevacizumab while the levels of other angiogenic complexes are relatively stable before and after bevacizumab treatment. The high expression of VEGFR1 can efficiently compete for VEGF, thereby limiting the benefits of VEGF neutralization through bevacizumab. On the other side, high expression of CD36 provides more available receptors for ABT-510 to bind to, which enables the formation of more anti-angiogenic complexes to shift the angiogenic balance. Since CD47 has a high affinity for TSP1, increasing the expression of CD47 will significantly elevate the baseline level of anti-angiogenic complexes.
This means that the tumor has a higher baseline anti-angiogenic signal and consequently shows an attenuated response to the benefit of forming more anti-angiogenic complexes through ABT-510. The insights generated by our model can guide future experimental or clinical studies of predictive biomarkers for anti-angiogenic treatment.
The predictions of our model also provide insight into outcomes from clinical trials involving antiangiogenic agents. ABT-510 failed in Phase II clinical trials for advanced renal cell carcinoma and metastatic melanoma 16, 17 . According to our model simulations, low CD36 expression on tumor cell could lead to the low observed response to ABT-510. Interestingly, the Human Protein Atlas shows CD36 is not detected in human renal cancer samples (in 10 out of 10 samples) and melanoma samples (in 11 out of 11 samples) 27 . The heterogeneous expression of CD36 might be a possible reason for the failure of ABT-510. In the combination of bevacizumab and ABT-510 for advanced solid tumors, only 32% percent of the patients have prolonged stable disease for more than 6 months 20 , which shows no evidence of being better than bevacizumab alone. Our model predicts that the difference between combination therapy and the best response of individual bevacizumab or ABT-510 treatment will become zero when the response to ABT-510 is very low. This means that the combination will not be superior to bevacizumab if ABT-510 alone is highly ineffective, which provides a possible explanation for the clinical observations.
Although we specifically simulate the combination of bevacizumab and ABT-510 in this work, our model can be adapted to study other anti-angiogenic agents that target VEGF and TSP1 signaling and help explore different anti-angiogenic strategies. Given the many different antiangiogenic agents 7, 15 and possible drug regimens, our realistic model could be a valuable help in the search for the optimal combination anti-angiogenic strategy. Additionally, this model has practical interest, which can help circumvent difficulty in experimental studies. Traditional experiment-based study of comparing the effects of combination therapy to individual agents is limited by the difficulty of accumulating enough data to make meaningful comparisons. In contrast, our model can easily simulate multiple anti-angiogenic treatment strategies and quantitatively evaluate the added benefit of combination therapy as compared to single-agent therapy. In this study, we show that the combination of bevacizumab and ABT-510 leads to a better response than administering either agent alone, in all of the sampled cases. However, the combination index revealed that the combination of these two drugs does not always have a strong synergistic effect, due to tumor receptor expression. This information underlines the need to consider tumor receptor heterogeneity in the design of drug combination strategies. Our model might help identify drug regimens that take advantage of the synergy and aids the design of anti-angiogenic therapy in order to achieve high efficacy with low drug dosage.
We acknowledge some limitations of the model that can be addressed in future studies. In this study, we use the angiogenic ratio to represent the angiogenic state, assuming that each angiogenic complex equally contributes to angiogenesis. However, it is known that the angiogenic receptors have unique functions and influence angiogenesis in different ways. For example, VEGFR1 primarily modulates blood vessel angiogenesis by ligand-trapping and receptor dimerization, while VEGFR2 is the predominant receptor that promotes pro-angiogenic VEGF signaling pathways 50, 51 . On the anti-angiogenic side, CD36 and CD47 are reported to inhibit angiogenesis by antagonizing survival pathways and activating apoptotic pathways 52 .
This knowledge of the relevant intracellular signaling pathways can be combined with our model to study specific functional responses to anti-angiogenic therapy. Secondly, it is worth noting that there are alternate ways of characterizing the magnitude of the response to anti-angiogenic therapy. We focus on the angiogenic ratio, where the balance of pro-and anti-angiogenic factors has been experimentally shown to be a more accurate approach to study angiogenesis than analyzing the level of angiogenic factors individually 53 . We further calculate the fold-change of the angiogenic ratio to characterize the response to anti-angiogenic treatment, while the area under the angiogenic ratio curve for the tumor compartment could be an alternative way to quantify the response to treatment. In that case, the response to ABT-510 is more substantial due to the strong shifting of the angiogenic ratio in the short time after each bolus (data not shown). However, the conclusions of our study remain unchanged. Another metric to consider is whether anti-angiogenic treatment shifts the angiogenic balance in tumor to the level observed in healthy tissue, related to vessel normalization 54 . Since a universal definition of the response to anti-angiogenic therapy is still missing, the fold-change of the angiogenic balance of pro-and anti-angiogenic receptor complexes remains as an important indicator, which this research is well suited to address.
Concluding thoughts. Our model illustrates the effect of combination therapy of bevacizumab and ABT-510 on changing the balance between two opposing angiogenic signals. The model provides a quantitative description of the impact of tumor receptor heterogeneity on the response to combination anti-angiogenic therapy and aids in the discovery of predictive biomarkers. We expect that the insights generated by our model predictions will shed light on previously obscure clinical observations and that the model will be used to facilitate the optimization of new clinical trials. 
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